The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of disease status prior to T-cell depleted allogeneic stem cell transplantation on relapse-free and overall survival in patients with adverse-risk acute myeloid leukemia (AML).
 
Alexandra Ewa Rojek
No Relationships to Disclose
 
Mylove Mortel
No Relationships to Disclose
 
Andrew S. Artz
Stock and Other Ownership Interests - Radiology Partners (I)
Consulting or Advisory Role - Abbvie; Magenta Therapeutics
 
Richard A. Larson
Consulting or Advisory Role - AbbVie; Actinium Pharmaceuticals; Curis; CVS Caremark; Epizyme; Immunogen; Jazz Pharmaceuticals; Kling Biotherapeutics; Novartis; Rigel; SERVIER; Takeda Science Foundation
Research Funding - Astellas Pharma (Inst); Celgene (Inst); Cellectis (Inst); Daiichi Sankyo (Inst); Gilead/Forty Seven; Novartis (Inst); Rafael Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Hongtao Liu
Consulting or Advisory Role - Agios; BeiGene; CTI BioPharma Corp; NGM Biopharmaceuticals; Nkarta; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Karyopharm Therapeutics (Inst)
 
Mariam Nawas
No Relationships to Disclose
 
Olatoyosi Odenike
Consulting or Advisory Role - Abbvie; Blueprint Medicines; BMS; Bristol-Myers Squibb/Celgene (Inst); Celgene; CTI; Impact Biomedicines; Kymera; Novartis; SERVIER; Taiho Pharmaceutical; Threadwell therapeutics
Research Funding - Abbvie (Inst); Agios (Inst); Aprea AB (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CTI BioPharma Corp (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Janssen Oncology (Inst); Kartos Therapeutics (Inst); Loxo (Inst); Novartis (Inst); NS Pharma (Inst); OncoTherapy Science (Inst)
 
Wendy Stock
Honoraria - Abbvie; Pfizer
Consulting or Advisory Role - AstraZeneca; BEAm; Deciphera; GlaxoSmithKline; Jazz Pharmaceuticals; Kite, a Gilead company; Kronos Bio; Kura Oncology; morphosys; Newave Pharmaceutical; Pfizer; Pluristem Therapeutics; SERVIER
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date
Travel, Accommodations, Expenses - Pfizer
 
Michael Russell Bishop
Honoraria - Bristol-Myers Squibb/Celgene/Juno; Incyte; Incyte; Sanofi/Aventis
Consulting or Advisory Role - Arcellx; Autolus; BMS; crispr therapeutics; Iovance Biotherapeutics; Kite, a Gilead company; Novartis; Sana Biotechnology
Speakers' Bureau - Agios; Bristol-Myers Squibb; Incyte; Kite, a Gilead company; Sanofi
Research Funding - Arcellx (Inst); crispr therapeutics (Inst); Iovance Biotherapeutics (Inst); Kite, a Gilead company (Inst); Novartis (Inst)
Expert Testimony - Johnson & Johnson/Janssen
Travel, Accommodations, Expenses - BMS; Kite/Gilead; Novartis
 
Satyajit Kosuri
No Relationships to Disclose